Effects of CD20 antibodies and kinase inhibitors on B-cell receptor signalling and survival of chronic lymphocytic leukaemia cells.

British Journal of Haematology
Chiara CavalliniMaria T Scupoli

Abstract

Recently, clinical trial results have established inhibitors of B-cell receptor (BCR)-associated kinase (BAKi), with or without CD20 moniclonal antibodies (mAbs), as the preferred first-line treatment for most chronic lymphocytic leukaemia (CLL) patients. Using phosphospecific flow cytometry, we showed that in leukaemic cells from CLL patients the CD20 therapeutic antibodies - rituximab, ofatumumab, and obinutuzumab - inhibited BCR signalling pathways targeting preferentially pBTKY551 - but not BTKY223 - and pAKT. On the contrary, ibrutinib and idelalisib reduced pBTKY223 to a higher extent than pBTKY551 . The strong reduction of pAKT induced by idelalisib was enhanced by its combination with rituximab or ofatumumab. Moreover, CD20 mAbs and BAKi induced the death of leukaemia cells that was significantly potentiated by their combination. Analysis of the enhancement of cell death in these combinations revealed an approximately additive enhancement induced by rituximab or obinutuzumab combined with ibrutinib or idelalisib. Taken together, our data identified negative regulatory effects of CD20 mAbs and their combinations with BAKi on BCR signalling and cell survival in CLL. In conclusion, this study advances our understanding of ...Continue Reading

References

Feb 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·Y YamanashiT Yamamoto
Oct 23, 1997·Proceedings of the National Academy of Sciences of the United States of America·M I WahlD J Rawlings
Feb 28, 2001·Proceedings of the National Academy of Sciences of the United States of America·Y BabaS Tsukada
Sep 5, 2007·Molecular Immunology·Martin J GlennieRonald P Taylor
Oct 29, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Mario I VegaBenjamin Bonavida
Dec 8, 2009·Blood·Samar KheirallahChristine Bezombes
Dec 1, 2006·Current Hematologic Malignancy Reports·Benjamin Bonavida
Jul 12, 2012·Expert Review of Hematology·Maria Teresa Scupoli, Giovanni Pizzolo
Dec 12, 2012·Cancer Treatment Reviews·Marcin OkrojAnna M Blom
Jun 21, 2013·The New England Journal of Medicine·John C ByrdSusan O'Brien
Jan 24, 2014·The New England Journal of Medicine·Richard R FurmanSusan M O'Brien
Mar 22, 2014·Blood·Holbrook E KohrtJohn C Byrd
Jun 25, 2014·British Journal of Haematology·Jiao MaY Lynn Wang
Feb 12, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Qingshan YangVarsha Gandhi
Aug 19, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Martin SkarzynskiAdrian Wiestner
Jan 20, 2018·Nature Reviews. Cancer·Jan A Burger, Adrian Wiestner
Feb 27, 2018·Lancet·Michael HallekBarbara Eichhorst
May 20, 2018·Nature Reviews. Clinical Oncology·Jan A Burger, Susan O'Brien
Dec 7, 2018·The New England Journal of Medicine·Jennifer A WoyachJohn C Byrd

❮ Previous
Next ❯

Citations

Aug 11, 2021·Expert Opinion on Emerging Drugs·Jennifer L Crombie, Jennifer R Brown
Oct 16, 2021·Hematological Oncology·Haoran WangKeshu Zhou

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.